Publications by authors named "Jean Solarz"

Article Synopsis
  • Down syndrome is a common chromosomal disorder associated with blood issues, particularly mild to moderate thrombocytopenia (low platelet count), which doesn't typically lead to bleeding problems.
  • Researchers studied the effects of Dyrk1A overexpression in mice and found it resulted in a 20% decrease in platelet count and a surprising 50% reduction in bleeding time.
  • The study revealed that the changes were linked to increased levels of fibronectin and fibrinogen in the plasma and liver, suggesting Dyrk1A has a new role in promoting these proteins, which may explain the observed discrepancies in bleeding tendencies.
View Article and Find Full Text PDF

Background: X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia (XMEN) disease is a primary immunodeficiency due to loss-of-function mutations in the gene encoding for magnesium transporter 1 (MAGT1). Furthermore, as MAGT1 is involved in the N-glycosylation process, XMEN disease is classified as a congenital disorder of glycosylation. Although XMEN-associated immunodeficiency is well described, the mechanisms underlying platelet dysfunction and those responsible for life-threatening bleeding events have never been investigated.

View Article and Find Full Text PDF

Dedicator of cytokinesis (DOCK) proteins play a central role in actin cytoskeleton regulation. This is highlighted by the DOCK2 and DOCK8 deficiencies leading to actinopathies and immune deficiencies. DOCK8 and DOCK11 activate CDC42, a Rho-guanosine triphosphate hydrolases involved in actin cytoskeleton dynamics, among many cellular functions.

View Article and Find Full Text PDF

The lack of innovation in von Willebrand disease (VWD) originates from many factors including the complexity and heterogeneity of the disease but also from a lack of recognition of the impact of the bleeding symptoms experienced by patients with VWD. Recently, a few research initiatives aiming to move past replacement therapies using plasma-derived or recombinant von Willebrand factor (VWF) concentrates have started to emerge. Here, we report an original approach using synthetic platelet (SP) nanoparticles for the treatment of VWD type 2B (VWD-2B) and severe VWD (type 3 VWD).

View Article and Find Full Text PDF

Background: Filaminopathies A are rare disorders affecting the brain, intestine, or skeleton, characterized by dominant X-linked filamin A (FLNA) gene mutations. Macrothrombocytopenia with functionally defective platelets is frequent. We have described a filaminopathy A male patient, exhibiting a C-terminal frame-shift FLNa mutation (Berrou et al.

View Article and Find Full Text PDF